Back to Awarded Treatment Trials
Awarded Trial: 05T-743
Grant ID
05T-743
Illness
Schizophrenia
Primary Drug/Intervention
BF2.649
Primary Dosage
40 mg.day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Tamminga
Sample Size
60
Duration of Study Period for Each Subject
20 weeks
Outcome Measurements
PANSS, CGI, MADRS, Suicidal Ideation Scale, Wakefullness Scale, Appetite VAS
Results
65 patients with schizophrenia or schizoaffective disorder were randomized to receive either BF2.649 or placebo for 8 weeks in addition to their usual antipsychotic drugs. This randomized controlled trial tested the efficacy of the drug in reducing cognitive deficits. No significant improvements were detected in the treatment group.
Publication
N/A
Link
N/A
PI Name
Carol Tamminga
Degree
MD
Center
Department of Psychiatry
Institution
UT Southwestern Medical Center
Address
5323 Harry Hines Boulevard
City or Town
Dallas
State or Province
TX
Zip or Postal Code
75390
Country
USA
Email Address
carol.tamminga@utsouthwestern.edu